153 related articles for article (PubMed ID: 19808643)
1. Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.
Thor AD; Edgerton SM; Jones FE
Am J Pathol; 2009 Nov; 175(5):1802-9. PubMed ID: 19808643
[TBL] [Abstract][Full Text] [Related]
2. The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium.
Rokicki J; Das PM; Giltnane JM; Wansbury O; Rimm DL; Howard BA; Jones FE
Mol Cancer; 2010 Jun; 9():150. PubMed ID: 20550710
[TBL] [Abstract][Full Text] [Related]
3. The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer.
Fujiwara S; Hung M; Yamamoto-Ibusuk CM; Yamamoto Y; Yamamoto S; Tomiguchi M; Takeshita T; Hayashi M; Sueta A; Iwase H
Oncotarget; 2014 Jun; 5(11):3919-30. PubMed ID: 25003574
[TBL] [Abstract][Full Text] [Related]
4. HER4 selectively coregulates estrogen stimulated genes associated with breast tumor cell proliferation.
Han W; Jones FE
Biochem Biophys Res Commun; 2014 Jan; 443(2):458-63. PubMed ID: 24333426
[TBL] [Abstract][Full Text] [Related]
5. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.
Jones FE
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):247-58. PubMed ID: 18473151
[TBL] [Abstract][Full Text] [Related]
6. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
7. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.
Naresh A; Thor AD; Edgerton SM; Torkko KC; Kumar R; Jones FE
Cancer Res; 2008 Aug; 68(15):6387-95. PubMed ID: 18676864
[TBL] [Abstract][Full Text] [Related]
8. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.
Naresh A; Long W; Vidal GA; Wimley WC; Marrero L; Sartor CI; Tovey S; Cooke TG; Bartlett JM; Jones FE
Cancer Res; 2006 Jun; 66(12):6412-20. PubMed ID: 16778220
[TBL] [Abstract][Full Text] [Related]
9. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells.
Zhu Y; Sullivan LL; Nair SS; Williams CC; Pandey AK; Marrero L; Vadlamudi RK; Jones FE
Cancer Res; 2006 Aug; 66(16):7991-8. PubMed ID: 16912174
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay.
Pawlowski V; Révillion F; Hebbar M; Hornez L; Peyrat JP
Clin Cancer Res; 2000 Nov; 6(11):4217-25. PubMed ID: 11106235
[TBL] [Abstract][Full Text] [Related]
11. HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen.
Göthlin Eremo A; Tina E; Wegman P; Stål O; Fransén K; Fornander T; Wingren S
Int J Oncol; 2015 Oct; 47(4):1311-20. PubMed ID: 26238412
[TBL] [Abstract][Full Text] [Related]
12. Direct coupling of the HER4 intracellular domain (4ICD) and STAT5A signaling is required to induce mammary epithelial cell differentiation.
Han W; Sfondouris ME; Jones FE
Biochem Biophys Rep; 2016 Sep; 7():323-327. PubMed ID: 28955922
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic HER4/4ICD transcriptional activation domains are required for STAT5A activated gene expression.
Han W; Sfondouris ME; Semmes EC; Meyer AM; Jones FE
Gene; 2016 Oct; 592(1):221-226. PubMed ID: 27502417
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
16. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
[TBL] [Abstract][Full Text] [Related]
18. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
[TBL] [Abstract][Full Text] [Related]
19. Prognostic markers in triple-negative breast cancer.
Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO
Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of ERM gene expression in human primary breast cancers.
Chotteau-Lelièvre A; Révillion F; Lhotellier V; Hornez L; Desbiens X; Cabaret V; de Launoit Y; Peyrat JP
Clin Cancer Res; 2004 Nov; 10(21):7297-303. PubMed ID: 15534105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
